Biology of Blood and Marrow Transplantation
Volume 15, Issue 1, Supplement , Pages 33-38 , January 2009

Plasma Biomarkers in Graft-versus-Host Disease: A New Era?

  • Sophie Paczesny

      Affiliations

    • Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
    • Corresponding Author InformationCorrespondence and reprint requests: Sophie Paczesny, MD, PhD, University of Michigan Comprehensive Cancer Center 6420,1500 E Medical Center Dr. Ann Arbor, MI 48109-5942, Ph# 734-615-3342, Fax# 734-615-3947.
    • ,
  • John E. Levine

      Affiliations

    • Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
    • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
    • ,
  • Thomas M. Braun

      Affiliations

    • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan
    • ,
  • James L.M. Ferrara

      Affiliations

    • Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
    • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan

References 

  1. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  2. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821–1828
  3. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant. 1996;17:185–190
  4. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant. 1998;21:29–32
  5. Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant. 1998;21:769–773
  6. Nakamura H, Komatsu K, Ayaki M, et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol. 2000;106:S45–S50
  7. Shaiegan M, Iravani M, Babaee GR, et al. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transplant Immunol. 2006;15:223–227
  8. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol. 2003;31:1044–1050
  9. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  10. Kayaba H, Hirokawa M, Watanabe A, et al. Serum markers of graft-versus-host disease after bone marrow transplantation. J Allergy Clin Immunol. 2000;106:S40–S44
  11. Or R, Kalinkovich A, Nagler A, et al. Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation–related complications. Cytokines Mol Ther. 1996;2:243–250
  12. Okamoto T, Takatsuka H, Fujimori Y, et al. Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant. 2001;28:197–200
  13. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003;17:1150–1156
  14. Uguccioni M, Meliconi R, Nesci S, et al. Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood. 1993;81:2252–2256
  15. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation. 1998;66:863–871
  16. Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant. 1994;13:745–751
  17. Mohty M, Blaise D, Faucher C, et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2005;106:4407–4411
  18. Fujimori Y, Takatsuka H, Takemoto Y, et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2000;109:652–657
  19. Symington FW, Pepe MS, Chen AB, et al. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation. 1990;50:518–521
  20. Luft T, Conzelmann M, Benner A, et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood. 2007;15;110(13):4535-42
  21. Piper KP, Horlock C, Curnow SJ, et al. CXCL10–CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem cell transplantation. Blood. 2007;1;110(12):3827-32
  22. Seidel C, Ringden O, Remberger M. Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation. 2003;76:423–426
  23. Hori T, Naishiro Y, Sohma H, et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood. 2008;111:4403–4412
  24. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:340–349
  25. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007;109:5511–5519
  26. Srinivasan R, Daniels J, Fusaro V, et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol. 2006;34:796–801
  27. Wang H, Clouthier SG, Galchev V, et al. Intact protein–based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteom. 2005;4:618–625
  28. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667–674
  29. Paczesny. S, Krijanovski Ol, Braun TM, Choi SW, Cloutheir SG, Kuick R, et al. biomarker panel for acute graft-versus-host disease. Blood. 2008 Oct 2.[Epub ahead of print].
  30. Faca V, Pitteri SJ, Newcomb L, et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res. 2007;6:3558–3565
  31. States DJ, Omenn GS, Blackwell TW, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol. 2006;24:333–338
  32. Zhang H, Liu AY, Loriaux P, et al. Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteom. 2007;6:64–71

 Financial disclosure: See Acknowledgments on page 37.

PII: S1083-8791(08)00475-8

doi: 10.1016/j.bbmt.2008.10.027

Biology of Blood and Marrow Transplantation
Volume 15, Issue 1, Supplement , Pages 33-38 , January 2009

Article Tools

* Image Usage & Resolution